|Bid||2.1900 x 3000|
|Ask||2.2000 x 2900|
|Day's Range||2.1500 - 2.2200|
|52 Week Range||2.1300 - 3.8600|
|Beta (5Y Monthly)||0.89|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 04, 2020 - Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jun 02, 2016|
|1y Target Est||N/A|
PDL BioPharma has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has completed the previously announced spin-off of its femtosecond laser system business, LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR").
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announced that its Board of Directors has approved the separation of LENSAR, Inc. ("LENSAR"), a majority owned subsidiary of PDL, from PDL in the form of a dividend involving the distribution of all outstanding shares of LENSAR common stock owned by PDL to holders of PDL common stock. Under the terms of the distribution: